PT  - JOURNAL ARTICLE
AU  - Alexander, Lori
ED  - Mehilli, Julinda
TI  - Bavarian Reperfusion Alternatives Evaluation-3 Trial
DP  - 2008 Jun 01
TA  - MD Conference Express
PG  - 9--10
VI  - 8
IP  - 2
4099  - http://mdc.sagepub.com/content/8/2/9.2.short
4100  - http://mdc.sagepub.com/content/8/2/9.2.full
AB  - For patients with acute ST-elevation myocardial infarction (STEMI) who undergo primary coronary intervention, the addition of abciximab does not enhance the clinical benefits that are provided by pretreatment with high-dose clopidogrel, according to the findings of the Bavarian Reperfusion Alternatives Evaluation-3 [BRAVE-3] trial. Moreover, abciximab increases the risk of adverse clinical outcomes, suggesting that it should not be added to standard antiplatelet therapy in this patient population.